Navigation Links
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Date:3/15/2010

esentation describes interaction of nimotuzumab with a mutant form of EGFR called variant III (EGFRvIII). This variant is frequently expressed in glioblastomas and results in enhanced transformation, reduced apoptosis, and resistance to therapy. Nimotuzumab was demonstrated to bind to EGFRvIII with similar strength as to the non-mutant form of the EGF receptor. This adds to the extensive body of knowledge concerning development of nimotuzumab in brain tumours where the antibody demonstrated encouraging results in early clinical trials treating adult and pediatric gliomas. Nimotuzumab is currently in a phase III study in combination with radiation/temozolomide, against radiation/temozolomide alone, with preliminary results expected in the second half of 2010.

The poster entitled "Nimotuzumab, a humanized anti-epidermal growth factor receptor antibody, interacts with EGFRvIII" will be presented Monday April 19, from 9-12pm in Exhibit Hall A-C, Poster Section 31 (Abstract # 1778) by Maria L. Jaramillo, a scientist from the National Research Council Biotechnology Research Institute.

Abstracts for the posters will be posted at the time of presentation at www.ymbiosciences.com.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... for a moment that Silicon Graphics Inc. (better ... days before its Altix 3000 family of servers and superclusters ... SGI rolled out the latest version of its popular ... the Mountain View-based company, whose only manufacturing facility is in ...
... Internet programming? Is tech still an exciting space to work ... with computers was an introductory programming class in 1979 using ... fledgling Internet when I started college in 1985. There have ... programming and the business of information technology as interesting and ...
... giant Eli Lilly & Company recently expressed concern to ... HIPAA privacy rule may impede clinical research trials. , ... and approve thousands of patient authorizations for use and ... Crosley, chief privacy officer of Indianapolis-based Eli Lilly. ...
Cached Biology Technology:SGI, Introduces Powerful High End Visualization Tools 2SGI, Introduces Powerful High End Visualization Tools 3Interview: Billpoint Founder Jason May on eBay, Open Source 2Interview: Billpoint Founder Jason May on eBay, Open Source 3Interview: Billpoint Founder Jason May on eBay, Open Source 4
(Date:7/9/2014)... healthy women differ from bacteria in women with ... from Loyola University Chicago Stritch School of Medicine. ... in the American Society for Microbiology,s online journal ... play a role in female urinary health. , ... poorly understood, condition with symptoms similar to urinary ...
(Date:7/9/2014)... the Spanish National Cancer Research Centre (CNIO) have discovered ... also regulates cell division in stratified epitheliathose that form ... the oesophagus or the vaginain adult organisms. According to ... Nature Communications , this factor could also play ... stratified epithelia of the oesophagus and skin. , The ...
(Date:7/9/2014)... Researchers studying critically ill children with traumatic injuries ... patients are likely to develop a hospital-acquired infection. ... Hospital and published online in June in the ... larger efforts that could lead to the clinical ... to prevent or reverse immune system damage following ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... (January 24, 2014) A new study published in ... egg production has increased over the past 50 years, the ... footprint. Researchers conducted a lifecycle analysis of U.S. egg production ... the complete lifecycle from crops to hens to the farm ...
... novel high-throughput screening process, scientists have for the first time ... a toxic eye protein that can lead to early onset ... can damage the eye,s optic nerve and cause vision loss ... for optic nerve damage. Researchers have implicated a ...
... the human gut and their impact on human health and ... research today. To address the most recent advances in this ... the world will come together at the Gut Microbiota for ... 9, 2014. The meeting is hosted by the Gut Microbiota ...
Cached Biology News:Landmark egg production study reveals reduction in environmental impact over past 50 years 2Landmark egg production study reveals reduction in environmental impact over past 50 years 3Researchers discover potential drug targets for early onset glaucoma 2Researchers discover potential drug targets for early onset glaucoma 3Attend the Gut Microbiota for Health World Summit 2014 2
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: